Huda Zoghbi - Regeneron Pharmaceuticals Director

<div class='circular--portrait' style='background:#800000;color: #F8F8FF;font-size:4em;padding-top: 25px;;'>RP</div>
REGN -- USA Stock  

Report: 4th of August 2020  

Dr. Huda Y. Zoghbi, M.D., is an Independent Director of the Company. Dr. Zoghbi is currently a professor in the departments of Pediatrics, Molecular and Human Genetics, and Neurology and Neuroscience at Baylor College of Medicine, the director of the Jan and Dan Duncan Neurological Research Institute at Texas Children Hospital, and an investigator of the Howard Hughes Medical Institute. She was elected to the National Academy of Sciences, the Institute of Medicine, and the American Association for the Advancement of Science, and was awarded numerous recognitions for her work, including the Pearl Meister Greengard Prize, the March of Dimes Prize in Developmental Biology, and the Vanderbilt Prize in Biomedical Science
Age: 63  Director Since 2016  Ph.D    
914 847-7000
Zoghbi earned her B.Sc. from the American University of Beirut, received her M.D. from Meharry Medical College in Nashville, Tennessee, and completed her pediatrics residency and a joint residency in neurology and pediatric neurology at Baylor College of Medicine, where she then pursued postdoctoral research training in molecular genetics.

Huda Zoghbi Latest Insider Activity

Regeneron Pharmaceuticals Management Efficiency

Regeneron Pharmaceuticals has return on total asset (ROA) of 10.77 % which means that it generated profit of $10.77 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 21.13 %, meaning that it created $21.13 on every $100 dollars invested by stockholders. Regeneron Pharmaceuticals management efficiency ratios could be used to measure of how well the company is managing its routine affairs as well as how well it utilizes its assets and manages liabilities. Regeneron Pharmaceuticals Return on Invested Capital is quite stable at the moment as compared to the past year. The company's current value of Return on Invested Capital is estimated at about 0.25. Return on Sales is projected to rise to 0.27 this year, although the value of Return on Investment will most likely fall to 19.90. Regeneron Pharmaceuticals Total Assets Per Share are quite stable at the moment as compared to the past year. The company's current value of Total Assets Per Share is estimated at about 144.86. Asset Turnover is projected to rise to 0.61 this year, although the value of Net Current Assets as percentage of Total Assets will most likely fall to 36.01. Total Liabilities is projected to rise to about 4 B this year. Current Liabilities is projected to rise to about 2.3 B this year
The company currently holds 715.2 M in liabilities with Debt to Equity (D/E) ratio of 0.06, which may suggest the company is not taking enough advantage from borrowing. Regeneron Pharmaceuticals has a current ratio of 4.13, suggesting that it is liquid enough and is able to pay its financial obligations when due.

Similar Executives

Showing few of many executives


J MoreauDr Reddys Laboratories
Dennis AusielloPfizer Inc
Patrick OSullivanAllergan Plc
Jacqualyn FousePerrigo Company Plc
Margaret McGlynnVertex Pharmaceuticals Incorpor
Joseph EchevarriaPfizer Inc
Michael GreenbergAllergan Plc
Linda RhodesZoetis Inc
Allan ObermanDr Reddys Laboratories
Ron TaylorAllergan Plc
James SmithPfizer Inc
James BloemAllergan Plc
Scott GottliebPfizer Inc
Kalpana MorpariaDr Reddys Laboratories
Stephen SangerPfizer Inc
Herman MorrisPerrigo Company Plc
Shlomo YanaiPerrigo Company Plc
Donal OConnorPerrigo Company Plc
Robert ScullyZoetis Inc
Dan LittmanPfizer Inc
Sridar IyengarDr Reddys Laboratories

Company Summary

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York. Regeneron Pharmaceuticals operates under Biotechnology classification in the United States and is traded on BATS Exchange. It employs 8030 people.Regeneron Pharmaceuticals (REGN) is traded on BATS Exchange in USA and employs 8,030 people.

Regeneron Pharmaceuticals Leadership Team

Charles Baker, Independent Director
Joseph Goldstein, Independent Director
Anthony Coles, Independent Director
George Sing, Independent Director
Peter Powchik, Senior Vice President - Clinical Development
Jay Markowitz, Senior Vice President - Portfolio Management
Robert Terifay, Sr. VP of Commercial
Robert Landry, CFO and Sr. VP of Fin.
Michael Brown, Independent Director
Christine Poon, Independent Director
Neil Stahl, Executive VP of RandD
Marion McCourt, Senior Vice President and Head of Commercial
George Yancopoulos, Chief Scientific Officer and President - Regeneron Laboratories, Director
Huda Zoghbi, Director
Bonnie Bassler, Director
Joseph LaRosa, Senior Vice President General Counsel, Secretary
Daniel Plew, Senior Vice President General Manager - Industrial Operations and Product Supply
Leonard Schleifer, President CEO, Director
Alfred Gilman, Independent Director
Roy Vagelos, Chairman of the Board
Michael Aberman, Vice President - Strategy
Manisha Narasimhan, IR Contact
Douglas McCorkle, Vice President Controller, Assistant Treasurer
Marc TessierLavigne, Independent Director
Christopher Fenimore, Vice President Controller
Arthur Ryan, Independent Director

Stock Performance Indicators

Did you try this?

Run Performance Analysis Now


Performance Analysis

Check effects of mean-variance optimization against your current asset allocation
All  Next Launch Module

Currently Active Assets on Macroaxis

Sold over 300 shares of
3 days ago
Traded for 8.62
Sold over 100 shares of
3 days ago
Traded for 25.24
Sold over 60 shares of
3 days ago
Traded for 44.08
Sold over 100 shares of
3 days ago
Traded for 28.82
Sold few shares of
3 days ago
Traded for 206.26
Additionally, take a look at Your Equity Center. Please also try Probability Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page